The number of cases of coccidioidomycosis and associated hospitalizations increased in California during 2000-2013. During that period, a total of 1,098 death records listed coccidioidomycosis as a cause, averaging 78 deaths annually (range: 43-108). The death rate peaked in 2006 and was significantly higher among males than among females, among African American patients than among white patients, and among residents of the coccidioidomycosisendemic region of California than among residents of the less endemic regions (p,0.001). A higher death rate was associated with increasing age and was highest (8.8 per 1 million population) among adults aged $75 years. Of coccidioidomycosis-associated deaths, 31.9% had a contributing cause of death of severe/disseminated disease, 31.8% of unspecified coccidioidomycosis, and 28.3% of pulmonary unspecified coccidioidomycosis, per International Classification of Diseases codes. Diabetes was a contributing cause in 19.3% of deaths, and other immunocompromising conditions were a contributing cause in 15.9% of deaths. Populations at higher risk for coccidioidomycosisassociated deaths are similar to those at higher risk for coccidioidomycosisassociated hospitalizations and infection. Awareness for coccidioidomycosis among these groups and their providers is important for proper diagnosis and care.
Public Health Reports / July-August 2016 / Volume 131 Coccidioidomycosis is primarily a respiratory infection caused by inhaling spores of Coccidioides fungi, which are endemic in dirt and soil of some areas of the southwestern United States. 1, 2 Approximately 40% of people who are infected develop symptoms, and approximately 1% develop disseminated disease. 3, 4 Severe disease is rare, but can be fatal. A review of 3,089 coccidioidomycosis-associated deaths in the United States during 1990-2008 found that California had the most deaths (n51,451, 47.0%). 5 The objective of our study was to describe the epidemiology of coccidioidomycosis-associated deaths in California from 2000 through 2013, to identify potential demographic and clinical risk factors for death, and to describe how they compare with risk factors for infection and hospitalization. Because the rates of new infections and initial hospitalizations of coccidioidomycosis increased in California during 2000-2011, [6] [7] [8] [9] we also sought to learn whether or not coccidioidomycosis-associated deaths increased during those years.
METHODS
We reviewed California multiple-cause-of-death files, a database of resident death certificates, to identify coccidioidomycosis-associated deaths, which we defined as deaths (1) during the study period, January 1, 2000, through December 31, 2013; and (2) with an underlying or contributing cause-of-death diagnosis code for coccidioidomycosis (International Classification of Diseases, 10th Revision [ICD-10] B38.0-B38.9). 10 Separately, we analyzed data on coccidioidomycosisassociated cases and hospitalizations in California during 2000-2013. We obtained these data from the California Department of Public Health's coccidioidomycosis surveillance system, a database of provider and laboratorian reports of confirmed coccidioidomycosis cases among California residents. We reviewed data on hospitalized patients from the California Patient Discharge Dataset, which contains administrative inpatient data reported by all California nonfederal hospitals. 11 We extracted hospitalization data on all patients whose records indicated a primary or secondary discharge diagnosis code for coccidioidomycosis. 9 We calculated annual case counts and rates by year of death, initial hospitalization admission, or symptom onset, and we stratified cases by sex, age group, race/ ethnicity, and region of patient residence (endemic or less endemic). We defined the endemic region in California to include Fresno, Kern, Kings, Madera, San Luis Obispo, and Tulare counties, which had annual incidence rates from 2001-2013 that were higher than the overall state rate. 10, 11 We defined the less endemic region of the state to include all other counties. We calculated death rates per 1 million population and incidence rates and initial hospitalization rates per 100,000 population by using population estimates from the California Department of Finance based on the 2010 U.S. Census. 12, 13 We age-adjusted rates to the 2000 U.S. standard population. For each dataset, we used Poisson regression to calculate bivariate relative risks (RRs) for sex, race/ethnicity, and region of residence. We then calculated RRs for race/ethnicity, controlling for sex and age group (,55 and $55 years). We considered p,0.05 to be statistically significant. We performed all analyses using SAS ® version 9.4. 14 We reviewed underlying and contributing causes of death listed on death certificates to identify the types of coccidioidomycosis and concurrent conditions associated with death. Types of coccidioidomycosis consisted of mutually exclusive categories ranked as follows: severe/disseminated (meningitis [ICD-10 B38.4]; cutaneous [ICD-10 B38.3], or disseminated [ICD-10 B38.7]); unspecified (other [ICD-10 B38.8]); pulmonary unspecified (chronic pulmonary [ICD-10 B38.1] or unspecified pulmonary [ICD-10 B38.2]); or acute pulmonary disease (ICD-10 B38.0). We identified death records with a diagnosis of diabetes (ICD-10 E08-E14) and other immunocompromising conditions, including malignant neoplasm, human immunodeficiency virus (HIV), rheumatologic disease, disorders of the blood or immune system, organ transplant, or severe malnutrition (ICD-10: C00-C797, C7A, D37-D48, B20-B24, M05-M06, M08, M12.0, M32-M36, M45-M49, L40.54, L40.59, D80-D89, D60, D61, D70-D72, T96, Z94, C80.2, D47.Z1, D89.81, and E40-E43).
RESULTS
During 2000-2013, a total of 1,098 coccidioidomycosisassociated deaths were recorded in California, yielding an average of 78 deaths (range: 43-108) annually. The mean annual age-adjusted death rate was 2.2 deaths per 1 million population (crude rate 5 2.2 deaths per 1 million population) (Table) . The number and rate of deaths peaked in 2006 (n5108 or 3.1 per 1 million population) and again in 2011 (n5101 or 2.7 per 1 million population). During the study period, a total of 39,201 cases and 18,521 hospitalized patients were reported; incidence rates increased from 2.4 to 8.5 per 100,000 population and hospitalization rates increased from 2.4 to 3.4 per 100,000 population, with both peaking in 2011 ( Figure) .
The average coccidioidomycosis death rate per 1 million population was significantly higher among males (rate 5 3.7, RR53.24, p,0.001) than among females Public Health Reports / July-August 2016 / Volume 131 
DISCUSSION
During 2000-2013, California coccidioidomycosisassociated death rates, incidence rates, and hospitalization rates fluctuated; death rates peaked in 2006 and incidence and hospitalization rates peaked in 2011. Although we do not know what caused the decrease after 2011, it could be related to the California drought, which began in fall 2011. Coccidioides requires moist soil to grow. 15 The death records show that death in California could occur in patients with any type of coccidioidomycosis, including acute pulmonary disease, although, not surprisingly, severe/disseminated (31.9%), including meningeal (10.9%), coccidioidomycosis comprises a substantial proportion of coccidioidomycosisassociated deaths. Patients with diabetes and other immunocompromising conditions comprised only about 34% of those who died, leaving a majority of coccidioidomycosis-associated deaths without a known underlying contributing cause. Similar to our findings, the findings of a national study of coccidioidomycosis-associated deaths during 1990-2008 found higher death rates among males than among females and among older age groups than among younger age groups. 8 The higher death and hospitalization rates among older age groups could be related to an increase in the number of comorbid conditions and a weakened immune system in older adults. 16, 17 The national study of coccidioidomycosisassociated deaths reported the highest death rates among Native American and Hispanic patients; however, our study found the highest rates among African American patients, a group with increased risk for severe coccidioidomycosis. 18, 19 
Limitations
The death, case-patient, and hospitalization datasets did not share enough personal identifiers to be matched adequately for further analysis and comparison. It is likely that these datasets do overlap to some extent, particularly with a number of the hospitalizations reported among the cases. This overlapping may explain some of the similar findings between these datasets; however, compared with the case-patient data, the hospitalization and death datasets represent patients with more severe disease. The accuracy of death certificates is limited by the experience of the people completing them. For the hospitalization dataset, we included all primary and secondary hospital diagnoses for coccidioidomycosis, which may have overestimated the true burden of disease. In contrast, coccidioidomycosis may be underreported on death certificates, and underreporting would have underestimated the number of deaths caused by coccidioidomycosis. Lastly, data on type of coccidioidomycosis and concurrent conditions were not available for reported case patients.
CONCLUSION
In California, coccidioidomycosis-associated death rates peaked in 2006, increased in 2011, and decreased in 2012 and 2013. Similar to incidences and hospitalizations, coccidioidomycosis-associated deaths disproportionately affected males, African American and Hispanic people, older people, and those living in endemic areas. Population groups at higher risk for coccidioidomycosis and associated hospitalizations were also at higher risk for coccidioidomycosis-associated deaths. Raising awareness among these populations and their providers is important for proper diagnosis and care.
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